Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an o... Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0503 | -8.38333333333 | 0.6 | 0.6099 | 0.5309 | 161152 | 0.59208102 | CS |
4 | -0.1803 | -24.698630137 | 0.73 | 0.7312 | 0.5309 | 228251 | 0.6348356 | CS |
12 | -1.1303 | -67.2797619048 | 1.68 | 3.44 | 0.5309 | 1060142 | 1.21773839 | CS |
26 | -1.2803 | -69.9617486339 | 1.83 | 3.44 | 0.5309 | 567035 | 1.32491053 | CS |
52 | -0.7903 | -58.9776119403 | 1.34 | 3.44 | 0.5309 | 381491 | 1.44272601 | CS |
156 | -11.6003 | -95.4757201646 | 12.15 | 13.8 | 0.5309 | 234382 | 2.38909391 | CS |
260 | -11.6003 | -95.4757201646 | 12.15 | 13.8 | 0.5309 | 234382 | 2.38909391 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.